会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 53. 发明授权
    • Ethynylindole compounds
    • 乙炔基吲哚化合物
    • US08115014B2
    • 2012-02-14
    • US12644378
    • 2009-12-22
    • Kazuyuki OhmotoSatoshi ItadaniYoshisuke NakayamaJun TakeuchiManabu Fujita
    • Kazuyuki OhmotoSatoshi ItadaniYoshisuke NakayamaJun TakeuchiManabu Fujita
    • C07D209/04A61K31/405A61K31/40
    • C07D209/18
    • As a compound having a potent oral activity and a long-lasting cysLT1/cysLT2 receptor antagonistic activity, the compound of the formula (I): which exhibits potent antagonistic activity against the cysLT1/cysLT2 receptor, and have long-lasting effects even in case of oral administration, and therefore is useful as an oral agent for preventing and/or treating a variety of diseases, for example, respiratory disease (for example, asthma (bronchial asthma, etc.), chronic obstructive pulmonary disease (COPD), pulmonary emphysema, chronic bronchitis, pneumonia (interstitial pneumonia, etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), apnea syndrome, allergic rhinitis, sinusitis (acute sinusitis, chronic sinusitis, etc.), pulmonary fibrosis, coughing (chronic coughing, etc.), and the like) was developed.
    • 作为具有有效的口服活性和持久的cysLT1 / cysLT2受体拮抗活性的化合物,式(I)化合物:其对cysLT1 / cysLT2受体具有强的拮抗活性,并且即使在例如 因此可用作预防和/或治疗各种疾病的口服药物,例如呼吸系统疾病(例如哮喘(支气管哮喘等),慢性阻塞性肺病(COPD),肺部 肺气肿,慢性支气管炎,肺炎(间质性肺炎等),严重急性呼吸综合征(SARS),急性呼吸窘迫综合征(ARDS),呼吸暂停综合征,过敏性鼻炎,鼻窦炎(急性鼻窦炎,慢性鼻窦炎等),肺纤维化 ,咳嗽(慢性咳嗽等)等)。